RESUMEN
Alveolar soft part sarcoma (ASPS) is a rare and highly malignant mesenchymal tumor that primarily affects adolescents and young adults. ASPS is characterized by a slow growth rate, high metastatic potential, and resistance to conventional therapies. The emergence of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced malignancies, improving the objective response rate (ORR) and prolonging patient survival. The combination of immunotherapy with targeted therapies can overcome resistance to treatment with ICIs alone. Although substantial progress has been made in various solid tumors, the clinical relevance of ICIs, used alone or in combination with other therapies, in patients with ASPS remains unclear. This is a case report of a 32-year-old man who was diagnosed with advanced ASPS. After 8 months of anlotinib treatment, the patient's disease progressed and new cerebellar metastases were detected. Radiotherapy was administered in addition to camrelizumab combined with apatinib to treat the brain metastases. The patient achieved partial remission (46%) after 3 months of treatment and did not present any severe side effects. This is the first reported case of the successful treatment of advanced ASPS with camrelizumab combined with apatinib. This case supports the use of a novel treatment regimen for patients with inoperable ASPS or ASPS that is resistant to conventional therapies.
Asunto(s)
Sarcoma de Parte Blanda Alveolar , Adolescente , Adulto , Anticuerpos Monoclonales Humanizados/uso terapéutico , Humanos , Masculino , Piridinas/uso terapéutico , Sarcoma de Parte Blanda Alveolar/tratamiento farmacológico , Adulto JovenRESUMEN
The purpose of the present prospective study was to evaluate the use of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the assessment of therapy response and the prediction of short-term outcomes by maximum and mean standardized uptake values (SUVmax and SUVmean, respectively), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) following chemoradiotherapy (CRT) in patients with stage III adenocarcinoma of the lung. The study included a total of 15 patients, all of whom underwent two serial 18F-FDG PET/CT scans prior to and following 60-Gy radiotherapy with a concurrent cisplatin/pemetrexed combined chemotherapy regimen. SUVmax, SUVmean, MTV and TLG were determined. Short-term outcomes were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) and the PET Response Criteria in Solid Tumors (PERCIST). Post-CRT SUVmax, ΔSUVmax, ΔMTV and ΔTLG varied significantly between responders and non-responders (P=0.009, P=0.015, P=0.006 and P=0.004, respectively). The differences in SUVmax, SUVmean, carcinoembryonic antigen, MTV and TLG between the responders and the non-responders at the initial 18F-FDG PET/CT scans were not statistically significant (P>0.05). The overall response rate was significantly higher (P=0.01) when evaluated using PERCIST compared with evaluation using RECIST. It was concluded that post-CRT SUVmax, ΔSUVmax, ΔMTV and ΔTLG may be used to differentiate the responders from the non-responders following CRT for stage III adenocarcinoma of the lung. This would aid in deciding whether or not to increase dosages or to incorporate a boost treatment without the requirement to suspend therapy.
RESUMEN
OBJECTIVE: To determine the optimal approach for estimating the length of gross tumor and involvement of the lymph nodes with 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in esophagogastric junction carcinoma (EGJC). The result was verified with pathologic examination. MATERIALS AND METHODS: Twenty patients with diagnosed and untreated EGJC were enrolled. The length of the gross tumor was measured using different approaches with PET/CT: Standardized uptake value (SUV) 1.5-5.5 in intervals of 1.0 and 10%-50% of maximum SUV (SUVmax) on 18F-FDG PET/CT in intervals of 10%. The results were expressed as L1.0-L5.0, and L10%-L50%, respectively. The pathological length of gross tumor (Lpath) was calculated based on the shrinkage ratio of primary tumor. The measurable lymph nodes were measured on PET/CT preoperatively, labeled during operation, and examined for pathology. RESULTS: Lpath was 6.87 ± 2.25 cm, L30% and L2.5 were 6.61 ± 1.76 cm and 7.56 ± 1.89 cm, respectively. L30% was closer to Lpath than other % SUVmax, L2.5 was closer to Lpath than other absolute SUV thresholds. The diagnostic performance of 18F-FDG PET/CT for lymph nodes was best at the cutoff SUV of 2.7, providing sensitivity of 70% and a specificity of 83.7% for detecting lymph node metastases. CONCLUSIONS: The tumor length with 30% SUVmax as the threshold was closest to the actual pathological length of EGJC. The diagnostic efficiency of 18F-FDG PET/CT was best at the cutoff SUVmax of 2.7 for detecting lymph node metastases in EGJC.
Asunto(s)
Neoplasias Esofágicas/diagnóstico , Unión Esofagogástrica/diagnóstico por imagen , Unión Esofagogástrica/patología , Fluorodesoxiglucosa F18 , Tomografía Computarizada por Tomografía de Emisión de Positrones , Neoplasias Gástricas/diagnóstico , Anciano , Biopsia , Neoplasias Esofágicas/cirugía , Unión Esofagogástrica/cirugía , Femenino , Humanos , Ganglios Linfáticos/diagnóstico por imagen , Ganglios Linfáticos/patología , Metástasis Linfática , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Tomografía Computarizada por Tomografía de Emisión de Positrones/métodos , Curva ROC , Neoplasias Gástricas/cirugía , Carga TumoralRESUMEN
For localized the incidence of renal cell carcinoma (RCC), nephrectomy is the standard treatment. As RCC is generally regarded as a radiation-resistant tumor, the value of postoperative adjuvant radiotherapy is controversial. However, with new advance in radiotherapy (i.e., three-dimensional conformal radiation therapy [3DCRT] and intensity-modulated radiation therapy [IMRT]), target volume delineation, intensity modulation in treatment planning, and treatment delivery are more accurate with fewer adverse effect. A right renal tumor was identified in a 50-year-old man during a routine examination. T1N0M0 RCC was clinically diagnosed as the tumor was 3 cm × 3.5 cm and well-enhanced with intravenously infused contrast material in the arterial phase on computed tomography (CT). No metastases to regional lymph nodes or distant sites were evident. 3DCRT after the operation was carried out. A total dose of 50 Gy in 20 fractions over 28 days was delivered using a 15-MV X-ray. No clinical acute or chronic side effects were recorded during or after treatment, which was well tolerated. After radiotherapy, the patient came back to the hospital for a check regularly, with no evidence of recurrence and metastasis more than 11 years, and the CT for abdominal showed partial function of the right renal remained. The present case showed a good response with recovery after CRT of 50 Gy in 20 fractions for postoperative RCC. Although further experiences and longer follow-up are mandatory to conclude the optimal treatment schedule and efficacy of CRT for RCC, postoperative radiotherapy definitely reduces locoregional recurrences and with acceptable gastrointestinal toxicity if modern techniques (CRT and IMRT) are utilized.
Asunto(s)
Carcinoma de Células Renales/patología , Carcinoma de Células Renales/radioterapia , Neoplasias Renales/patología , Neoplasias Renales/radioterapia , Cuidados Posoperatorios , Carcinoma de Células Renales/cirugía , Terapia Combinada , Humanos , Neoplasias Renales/cirugía , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Hipofraccionamiento de la Dosis de Radiación , Radioterapia de Intensidad Modulada/métodos , Tomografía Computarizada por Rayos X , Resultado del TratamientoRESUMEN
Background: We obtained conflicting results regarding the relationship between the genetic role of the rs1138272 C/T polymorphism of the GSTP1 (Glutathione S-Transferase pi) gene and the risk of various cancers. Methods: Using the presently available data, a meta-analysis was conducted to comprehensively evaluate the genetic relationship between the GSTP1 rs1138272 polymorphism and cancer susceptibility. Results: A total of 43 studies including 15,688 cases and 17,143 controls were recruited into our quantitative synthesis. In the overall population, we observed an increased risk of overall cancer cases, compared with unrelated controls, in the genetic models of allele T vs. allele C (P-association = 0.007, OR = 1.17), carrier T vs. carrier C (P-association = 0.035, OR = 1.11), TT vs. CC (P-association = 0.002, OR = 1.45), TT vs. CC+CT (P-association = 0.009, OR = 1.42), and CT+TT vs. CC (P-association = 0.027, OR = 1.13). We detected similar positive results within the Asian population. Additionally, there was a significant increase in the incidence of cancer for Africans under all genetic models (all P-association < 0.05, OR > 1). When targeting the Caucasian population, we detected a positive association with the TT vs. CC and TT vs. CC+CT models in the "Colorectal cancer" (P-association < 0.05, OR < 1) and "Head and neck cancer" (P-association < 0.05, OR > 1) subgroups. For the "Lung cancer" subgroup, we observed a slightly increased risk in Caucasians under the models of allele T vs. allele C, carrier T vs. carrier C, CT vs. CC, and CT+TT vs. CC (P-association < 0.05, OR > 1). Conclusion: The TT genotype of the GSTP1 rs1138272 polymorphism is likely related to the susceptibility to overall cancer in the Asian and African populations and, specifically, "Colorectal" and "Head and neck" cancers in the Caucasian population. In addition, the CT genotype of the GSTP1 rs1138272 polymorphism may be linked to the risk of lung cancer in Caucasians. Additional evidence is required to confirm this conclusion.
RESUMEN
Immunomagnetic bead (IMB)-based enzyme-linked immunosorbent assay (ELISA) has been the tool frequently used for protein detection in research and clinical laboratories. For most ELISA reactions the recommended dosage of IMBs is usually according to their weight (mg) or mass fraction (w/v) instead of the bead number. Consequently, the processes occurring in the immediate vicinity of the IMBs have always been ignored by researchers and they cannot be revealed in detail during the ELISA reaction. In this paper, we established the relationship between number of IMBs and colorimetric results, and further proposed a new concept of "nominal effective immunoreaction volume (NEIV)" to characterize a single IMB during ELISA reaction. Results showed that the NEIV of a single IMB has a constant value, which is unrelated to the amount of beads and the concentration of antigen. Optimal results of the colorimetric ELISA are achieved when the incubation volume meets each IMB's NEIV and is no longer enhanced by increasing the incubation volume. Thus, the reliable and relatively precise number of IMBs for ELISA detection during practical application could be determined. Most importantly, a study using IMB's NEIV would lay the foundation for a kinetics analysis of IMBs and antigens for future study.
Asunto(s)
Ensayo de Inmunoadsorción Enzimática , Separación Inmunomagnética , HumanosRESUMEN
BACKGROUND: The urachus is a vestigial tubular structure that connects the urinary bladder to the allantois during early embryonic development. Urachal carcinoma develops in the urachus, which is an embryological remnant of the urogenital sinus and allantois. The estimated annual incidence of urachal carcinoma in the general population is 0.01% of all cancers in adults. Moreover, urachal carcinoma accounts for 0.34% to 0.7% of all bladder carcinoma cases. And breast metastasis is extremely rarer. METHODS AND RESULTS: A 42-year-old woman was admitted to our hospital with a palpable mass in the outer upper quadrant of the right breast, which was misinterpreted as a carcinoma that originated from the breast. Subsequently, she underwent surgery without any further meticulous examination. Immunohistochemistry analysis revealed positivity for CK20, Villin, and CDX-2 and negativity for CK7. After further inspection, a mass was found in the bladder dome using 18F-fluorodeoxyglucose positron emission tomography and computed tomography. The mass was surgically removed. CONCLUSION: Pathologic and immunohistochemical examination confirmed that the mass was urachal mucinous adenocarcinoma and mucinous adenocarcinoma to the right breast. The patient has been followed up without recurrence for 8 months.
Asunto(s)
Adenocarcinoma Mucinoso/diagnóstico , Adenocarcinoma/secundario , Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/secundario , Errores Diagnósticos , Neoplasias de la Vejiga Urinaria/patología , Adenocarcinoma/química , Adenocarcinoma/diagnóstico por imagen , Adulto , Neoplasias de la Mama/química , Neoplasias de la Mama/patología , Femenino , Humanos , Tomografía Computarizada por Tomografía de Emisión de Positrones , Neoplasias de la Vejiga Urinaria/química , Neoplasias de la Vejiga Urinaria/diagnóstico por imagen , Neoplasias de la Vejiga Urinaria/secundarioRESUMEN
Desmoplastic small round cell tumor (DSRCT) is a rare tumor that mainly affects adolescents, and typically involves the abdominal and pelvic peritoneum. The present study reports one case of giant DSRCT, treated with concurrent chemoradiotherapy, and reviews the available medical literature. A 38-year-old man presented with a 3-month history of pain in the left lower abdomen and nausea, associated with decreased appetite and weight loss. Computed tomography (CT) showed a 12.3×7.9 cm confluent solid mass in the lower abdomen and pelvic cavity. The patient underwent exploratory laparotomy and the final pathological diagnosis was DSRCT. Following laparotomy, the patient was treated with external beam radiotherapy to the whole abdomen and pelvis to a dose of 40 Gy plus a 20 Gy boost to the residual disease. The results indicated that synchronous chemotherapy with cyclophosphamide, adriamycin and cisplatin combined with radiotherapy significantly improved locoregional control of DSRCT and a complete response, as measured by CT assessment 2 months subsequent to radiotherapy. In conclusion, DSRCT is a rare malignancy requiring multidisciplinary treatment, including surgery, chemotherapy and radiotherapy. The results of the present study confirm that radiotherapy has a significant role in the treatment of advanced abdominal DSRCT and may contribute to durable remission.
RESUMEN
Solitary fibrous tumor of the pelvic is an uncommon neoplasm with nonspecific symptoms. Reports of malignant transformation are especially rare. We report a case of solitary fibrous tumor in pelvic. A unique feature of our case compared with previously reported is that this patient relapsed with malignant transformation and had significant response to radiotherapy. The patient was initially treated with surgery, followed by postoperative dimensional conformal intensity modulated radiation therapy (dynamic MLC VRIAN 23EX Linac, inversely optimized by the Eclipse system) to provide a radical cure for residual tumor.In this case, there were no signs of recurrence after six and a half years of further follow-up, indicating that postoperation radiotherapy may be an effective treatment for SFT with malignant transformation in pelvic.
Asunto(s)
Transformación Celular Neoplásica/patología , Recurrencia Local de Neoplasia/patología , Tumores Fibrosos Solitarios/patología , Tumores Fibrosos Solitarios/radioterapia , Biopsia con Aguja , Estudios de Seguimiento , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/radioterapia , Pelvis , Radioterapia Adyuvante , Radioterapia de Intensidad Modulada/métodos , Enfermedades Raras , Medición de Riesgo , Tumores Fibrosos Solitarios/cirugía , Tomografía Computarizada por Rayos X/métodos , Resultado del Tratamiento , Ultrasonografía DopplerRESUMEN
Retrorectal cystic hamartomas are rare congenital presacral lesions and malignancy is extremely rare. Although surgical excision is the essential for treatment, a unique feature of our case compared with previously reported tailgut cysts is that this patient's blood irregular antibodies are positive with higher operational risks.A 44-year-old woman presented to our department complaining of pelvic and perineal pain for 6 months. Computed tomography (CT) scan of the abdomen and pelvis demonstrated a well-demarcated hypodense, multilocular cystic lesion, 10âcm in size, in the presacral region of the right of the midline. We found her blood irregular antibodies were positive in the preoperative examination. So she quitted surgery. Exploratory laparotomy and incision and drainage of pelvic tumor were operated. Postoperative routine pathology showed: (retroperitoneal tumors) moderately differentiated adenocarcinoma. Combined with clinical symptom and imaging, malignant transformation of retrorectal cystic hamartomas (tailgut cysts) was diagnosed. Taking into account that cyst is not sensitive to radiotherapy, so tumor necrosis factor (TNF) and raltitrexed were infused into the cysts and 3 cycles oxaliplatin (130âmg/m) were completed. Now although the lesion is shrink, but yellow, viscous mucus still secrete constantly, 100âml/w.Given surgical excision is the essential for treatment, complete surgical excision should be implemented as far as possible. But if surgery cannot be carried out like the presented case, systemic chemotherapy and local radiotherapy are also available, which can alleviate the symptoms of oppression and improve the quality of life partly.
Asunto(s)
Adenocarcinoma/patología , Anticuerpos/sangre , Hamartoma/patología , Neoplasias del Recto/patología , Adenocarcinoma/terapia , Adulto , Femenino , Hamartoma/terapia , Humanos , Neoplasias del Recto/terapiaRESUMEN
The present study aimed to investigate the clinical characteristics, diagnosis and treatment of accessory breast cancer, and contribute valuable information regarding this rare tumour to the current literature, ultimately facilitating the development of improved treatment strategies. The present study reported the cases of 11 patients with accessory breast cancer. The patients with accessory breast cancer were admitted between January 2002 and June 2014, and the patient records were retrospectively analysed. All patients presented with a tumour that was localised in the axilla. Out of these patients, there were 8 patients with invasive ductal carcinoma and 3 patients with invasive lobular carcinoma. The follow-up periods for patients ranged between 4 and 54 months. Out of the 5 patients that experienced neoplasm metastases, 4 patients succumbed to the disease. In total, 6 patients remain alive with no evidence of disease. Accessory breast cancer is a progressive tumour, and long-term follow-up is required. A comprehensive treatment strategy may be an effective treatment option for patients; however, the optimal time at which to commence chemotherapy and the role of combined radiotherapy and endocrine therapy require additional investigation.
RESUMEN
A 48-year-old man with a solitary fibrous tumor of the pelvic underwent resection, but recurrent tumor was found 4 years later. Recurrent solitary fibrous tumor of the pelvic with malignant progression is rare. Solitary fibrous tumor of the pelvic often has an indolent clinical course, so postoperative surveillance may necessitate long-term follow-up because of the potential adverse biological behavior of this tumor, which may lead to repeated recurrences and/or malignant transformation.
RESUMEN
PURPOSE: Desmoplastic small round cell tumor (DSRCT) is a rare aggressive malignancy that occurs in a young population with a male predominance. We studied the clinical and pathological characteristics of DSRCT and investigated the effects of multimodal therapy including aggressive surgical resection, induction chemotherapy, and external beam radiotherapy. METHODS: We retrospectively reviewed and analyzed our experience with 11 histologically proven cases of DSRCT between March 2004 and October 2014. The clinical information, histological, immunohistochemistry and survival data of the patients were collected. RESULTS: The median age at diagnosis was 31.4 years (range, 14-64 years) and nine (82%) of the patients were males. The most common presenting complaint was abdominal pain (72.7%). Surgical resection was attempted in five patients and included macroscopic total resection in two patients and debulking in three patients. Six patients underwent biopsy only. Eleven patients received multiagent chemotherapy. Five patients (45.5%) received radiotherapy. The median survival of patients who underwent surgical resection was 34.5 months, whereas the patients who underwent biopsy alone was 24.5 months (P<0.05). The median survival was 40.8 months in radiotherapy group, and 19.2 months in non-radiotherapy group (P<0.05). The 3-year progression-free survival rate was 27.2%. The median survival was 29 months, and the median time to local failure was 8.8 months. Cox regression analysis showed surgery and radiotherapy were highly significant in prolonging patients survival. CONCLUSION: Multimodal therapy consists of combination of surgical resection, chemotherapy and radiotherapy results in improved survival in patients with DSRCT. For unresectable DSRCT, we recommend radiotherapy combined with anthracycline-based chemotherapy.
RESUMEN
The role of radiotherapy (RT) in the management of urinary bladder cancer has undergone several alterations along the last decades. Recently, many protocols have been developed supporting the use of multi-modality therapy, and the concept of organ preservation began to be reconsidered. Advances in radiotherapy planning, verification, and delivery provide a method to optimize radiotherapy for bladder cancer and overcome difficulties which have previously limited the success of this treatment. They offer the opportunity to enhance the therapeutic ratio by reducing the volume of normal tissue irradiated and by increasing radiation dose or using more intensive fractionation and synchronous chemotherapy regimes. These techniques have a large potential to improve the therapeutic outcome of bladder cancer. In the near future, it should be possible to offer selected patients with muscle-invasive bladder cancer an organ-sparing, yet effective combined-modality treatment. In this review, we aim to present the role of radiotherapy in the management of muscle invasive bladder cancer. Alternative methods of improving treatment accuracy such as helical tomotherapy, adaptive radiotherapy and radiochemotherapy are also discussed.
RESUMEN
PURPOSE: GRIM-19 has been shown to be down-regulated in cervical cancers. This study investigated the expression of GRIM-19 in cervical intra-epithelial neoplasias and its association with high-risk human papillomavirus (HR-HPV) infection. METHODS: The expression of GRIM-19 was assessed in cervical exfoliated cells and cervical intra-epithelial neoplasia tissues by immunohistochemistry, and the level of GRIM-19 was also evaluated by Western blotting using cervical exfoliated cells. HR-HPV infection of cervical exfoliated cells was detected by HC II. RESULTS: GRIM-19 is predominantly expressed in the cytoplasm of the middle layer of normal cervical epithelial cells, whereas the surface layer cells of the normal cervix showed no GRIM-19 expression. The expression of GRIM-19 gradually decreased from atypical squamous cells of undetermined significance (ASCUS), low-grade squamous intraepithelial lesion (LSIL) and high-grade squamous intraepithelial lesion (HSIL) to squamous cell carcinoma (SCC); a pattern which was also observed in cervical intra-epithelial neoplasias tissues. The reduced expression of GRIM-19 was correlated with HR-HPV infection. CONCLUSION: GRIM-19 may regulate the differentiation of normal cervical tissue, and a decrease in GRIM-19 may be the result of HR-HPV infection, which in turn leads to the malignant transformation of the cells.
Asunto(s)
Proteínas Reguladoras de la Apoptosis/metabolismo , Carcinoma de Células Escamosas/metabolismo , NADH NADPH Oxidorreductasas/metabolismo , Infecciones por Papillomavirus/etiología , Infecciones por Papillomavirus/metabolismo , Displasia del Cuello del Útero/metabolismo , Neoplasias del Cuello Uterino/metabolismo , Adulto , Carcinoma de Células Escamosas/complicaciones , Femenino , Humanos , Inmunohistoquímica , Neoplasias del Cuello Uterino/complicaciones , Adulto Joven , Displasia del Cuello del Útero/complicacionesRESUMEN
OBJECTIVE: To explore the relationships between primary tumor 18F-FDG uptake measured as the SUVmax and local extension, and nodal or distant organ metastasis in patients with NSCLC on pretreatment PET-CT. METHODS: 93 patients with NSCLC who underwent 18F-FDG PET-CT scans before the treatment were included in the study. Primary tumor SUVmax was calculated; clinical stages, presence of local extension, nodal and distant organ metastases were recorded. The patients with SUVmax ≥ 2.5 were divided into low and high SUVmax groups by using the median SUVmax. The low SUVmax group consisted of 45 patients with SUVmax<10.5, the high SUVmax group consisted of 46 patients with SUVmax ≥ 10.5. Their data were compared statistically. RESULTS: 91 cases with SUVmax≥2.5 were included for analysis. The mean SUVmax in patients without any metastasis was 7.42 ± 2.91 and this was significantly lower than that (12.18 ± 4.94) in patients with nodal and/or distant organ metastasis (P=0.000). In the low SUV group, 19 patients had local extension, 22 had nodal metastasis, and 9 had distant organ metastasis. In the high SUV group, 31 patients had local extension, 37 had nodal metastasis, and 18 had distant organ metastases. There was a significant difference in local extension (P =0.016), distant organ metastasis (P =0.046), and most significant difference in nodal metastasis rate (P =0.002) between the two groups. In addition, there was a moderate correlation between SUVmax and tumor size (r = 0.642, P<0.001), tumor stage (r = 0.546, P<0.001), node stage (r = 0.388, P<0.001), and overall stage (r = 0.445, P= 0.000). CONCLUSION: Higher primary tumor SUVmax predicts higher extensional or metastatic potential in patients with NSCLC. Patients with higher SUVmax may need a close follow-up and more reasonable individual treatment because of their higher extensional and metastatic potential.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/diagnóstico por imagen , Fluorodesoxiglucosa F18 , Neoplasias Pulmonares/diagnóstico por imagen , Metástasis de la Neoplasia/patología , Tomografía de Emisión de Positrones , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Pulmón de Células no Pequeñas/diagnóstico , Carcinoma de Pulmón de Células no Pequeñas/patología , Femenino , Humanos , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana Edad , Pronóstico , Radiofármacos , Estudios RetrospectivosRESUMEN
To investigate the clinical characteristics and outcome of patients with HIV-negative multicentric Castleman's disease (MCD) treated exclusively with combination chemotherapy, and review literature to improve the diagnosis and management of this disease. A retrospective study was performed on the medical records of 10 patients with HIV-negative MCD treated exclusively with combination chemotherapy at one medical institution from May 2004 to April 2012. And relevant clinical, pathological, radiographic, and laboratory data were examined in order to evaluate treatment responses, with symptom onsets and survival period serving as the endpoints of the assessment. All patients have multifocal lymphadenopathy, and the associated system symptoms are found in 80 % of the cases. All patients were treated with lymphoma-based chemotherapy alone. The duration of follow-up ranged from 5 to 77 months for nine patients. Four patients were treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) alone: One was alive with no evidence of disease, and three were alive with disease. Three patients received cyclophosphamide, vincristine, and prednisone (COP) alone: One remained alive with disease, and two experienced recurrences and passed away. Two had only minimal response to COP and were switched to CHOP, and they were still alive with disease. MCD is a more progressive clinical entity, and long-term follow-up is necessary. CHOP chemotherapy may be an effective treatment option for patients with MCD, whereas when to start chemotherapy, how many cycles of chemotherapy required, and the role of combined radiotherapy remain to be further studied.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Enfermedad de Castleman/tratamiento farmacológico , Adulto , Anciano , Enfermedad de Castleman/inmunología , Enfermedad de Castleman/patología , Ciclofosfamida/uso terapéutico , Doxorrubicina/uso terapéutico , Femenino , Seropositividad para VIH , Humanos , Masculino , Persona de Mediana Edad , Prednisona/uso terapéutico , Estudios Retrospectivos , Resultado del Tratamiento , Vincristina/uso terapéuticoRESUMEN
The objective of the present research was to study the influence of four kinds of light intensity of near-infrared diffuse reflectance spectra on the determination of pear soluble solids content. Qualitative analysis of the four spectra showed that the differences between them were too slight to find. After further analysis by principal component regression (PCR), stepwise multiple linear regression (SMLR) and partial least squares regression (PLSR) as well as comparisons among them, the results of PCR model and SMLR models which had low correlation coefficients (r) were worse than those of PLSR model. The model based on PLSR was further optimized by the second order derivative pretreatments of the spectra, and its correlation coefficients ranged from 0.947 to 0.970. The relative coefficients in PLSR model based on spectra from four sets were 0.958. The results indicate that light intensity has little influence on the determination of pear soluble solids content based on near-infrared diffuse reflection spectra.
Asunto(s)
Frutas , Pyrus , Espectroscopía Infrarroja Corta , Análisis de los Mínimos Cuadrados , Luz , Modelos Lineales , Análisis MultivarianteRESUMEN
Soilless culture has many virtues, such as space saving, time saving, etc.. It has become one of the technologies which developed fastest in agricultural products. The selection of substrate is one of the keys to determining the success of soilless culture. Therefore, it is important to rapidly determine the parameters of substrate. In the present paper, moisture, electronic conductivity and pH values of substrate were tested by near-infrared (NIR) spectroscopy. The spectra were preprocessed by baseline correction and derivative. Partial least squares (PLS) regression model was built using different wave bands. It was found that baseline drift was improved after correction. NIR spectroscopy can be used to determine EC value of substrate. The correlation coefficient r, root-mean-square error of the cross validation (RMSECV), relative percent difference (RPD) and bias of the optimum PLS was 0.923 6, 634 micros x cm(-1), 3.11 and 19.8 micros x cm(-1), respectively, when the best wave band was 4 246.7 - 7 502.2 cm(-1) and the best factor was 7. NIR spectroscopy technique can also be used to predict moisture of substrate although the accuracy of model should be improved. However, it can not be used to predict pH value of substrate.